加载中
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
前收盘价
US$1.51
US$0.00 · 0.00%
盘前
US$1.50
−US$0.01 · -0.66%
10月8日 7:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
日内区间
当前US$1.51
52周区间
当前US$1.51
盘中时间采用ET。市场数据可能有所延迟。
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
日内区间
当前US$1.51
52周区间
当前US$1.51
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 21.36万 USD | — | — | — | — |
| 毛利 | −21.36万 USD | — | — | — | — |
| 研究与开发 | 1149.88万 USD | 2613.62万 USD | 2726.63万 USD | 1921.96万 USD | 1758.65万 USD |
| 销售、一般及管理费用 | 1148.11万 USD | 2564.15万 USD | 1169.44万 USD | 959.41万 USD | 654.48万 USD |
| 营业费用 | 2276.62万 USD | 5177.77万 USD | 3896.06万 USD | 2881.38万 USD | 2413.13万 USD |
| 利息收入 | 43.51万 USD | 121.09万 USD | 38.71万 USD | 15.25万 USD | 2284 USD |
| 折旧和摊销 | 21.36万 USD | 29.17万 USD | 19.24万 USD | 14.84万 USD | 14.99万 USD |
| 营业利润 | −2297.98万 USD | −5177.77万 USD | −3896.06万 USD | −2881.38万 USD | −2413.13万 USD |
| 净利润 | −2179.1万 USD | −4458.14万 USD | −4277.06万 USD | −3179.26万 USD | −2412.24万 USD |
公司数据更新于 2026年10月8日。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
